Adding oral antihistamines to existing eczema treatments is unlikely to lead to clinically important reductions in eczema and itch severity and may not reduce sleep disturbance or flare-ups, finds a review of the latest trial evidence published by The BMJ today.

Some antihistamines may also increase side effects such as drowsiness and the risk of patients stopping treatment.

The researchers say this review addresses longstanding uncertainty surrounding the role of antihistamines in treating eczema, and the results do not support their use in routine eczema management.